RE:RE:RE:RE:So I just came back from the UKLattice: Cxr sold donnatel at $15 before for a profit, now it's at $60 which is just under the price of the new drug under patent that actually does treat IBS but with more side effects. That's smart business. If they have to pull a Walmart and took back the price so to speak then it can be done easily where Cxr is still very profitable and most likely will increase their market share. Lots of ifs and unknowns here and everyone is trying to gage the situation still. This is a Drug that costs pennies to make. You never know maybe selling donnatel is on the table as well